Results 11 to 20 of about 663,256 (217)
European Urology Open Science, 2023 The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer ...
Giuseppe Fallara +8 more
doaj +1 more source
High-dose-rate endobronchial brachytherapy in the management of advanced lung cancer - comparison according to the presence of lung atelectasis [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2021 Introduction/Objective. Locally advanced lung cancer is often accompanied by atelectasis of either a part or the entire lung. The aim of this study was to establish the benefits of brachytherapy on the patients’ quality of life, the length of the ...
Bojović Marko +7 more
doaj +1 more source
Progression‐free survival in oncology: Caveat emptor! [PDF]
Basic & Clinical Pharmacology & Toxicology, 2018 AbstractOverall survival (OS) is the undisputed gold standard efficacy end‐point in cancer drug trials. It is with growing concern that we observe how progression‐free survival (PFS) gains ground as surrogate end‐point in its place. PFS has appeal because it is resource‐efficient, but it has severe shortcomings.
Bergmann, Troels K +4 more
openaire +3 more sources
An Audit Strategy for Progression-Free Survival [PDF]
Biometrics, 2011 In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression-free survival (PFS) is one such endpoint.
Dodd, Lori E. +4 more
openaire +3 more sources
Medicina, 2022 Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a ...
Irena Conic +7 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect ...
Ziqi Ye +6 more
doaj +1 more source
Infectious Diseases and Therapy, 2023 Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu +14 more
doaj +1 more source
Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival [PDF]
JNCI: Journal of the National Cancer Institute, 2015 Broglio and Berry (2009) examined the impact of survival postprogression (SPP) on overall survival (OS) when progression-free survival (PFS) was used to assess treatment effect in metastatic cancer. Their simulation studies found no statistical difference in OS because of dilution effect from SPP, although there was a statistical difference in PFS ...
Morita, S, Sakamaki, K, Yin, G
openaire +4 more sources
Indonesian Journal of Cancer, 2021 Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr.
Brahmana Askandar Tjokroprawiro +2 more
doaj +1 more source
Pharmaceutics, 2022 Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet +15 more
doaj +1 more source